Invading pathogens may trigger overactivation of the innate immune system, which results in the release of large amounts of proinflammatory cytokines (cytokine storm) and leads to the development of pulmonary edema, multiorgan failure, and shock. PIAS1 is a multifunctional and potent anti-inflammatory protein that negatively regulates several key inflammatory pathways such as Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor kB (NF-kB). We discovered a ubiquitin E3 ligase, HECTD2, which ubiquitinated and mediated the degradation of PIAS1, thus increasing inflammation in an experimental pneumonia model. We found that GSK3b phosphorylation of PIAS1 provided a phosphodegron for HECTD2 targeting. We also identified a mislocalized HECTD2 polymorphism, HECTD2
INTRODUCTION
PIAS [protein inhibitor of activated signal transducers and activators of transcription (STATs)] proteins are a family of multifunctional proteins that are known to negatively regulate several key inflammatory pathways in cells (1) . Human PIAS proteins are encoded by four genes-PIAS1, PIASx (PIAS2), PIAS3, and PIASy (PIAS4) (1)-that are highly conserved. PIAS1 is known to suppress the activation of STATs and also binds to the p65 subunit of nuclear factor kB (NF-kB), preventing NF-kB-dependent gene activation (2) (3) (4) (5) (6) . In addition, PIAS1 has small ubiquitin-like modifier E3 ligase activity in its RING-type domain, allowing it to function similarly to a ubiquitin E3 ligase by posttranslationally modifying specific substrates. PIAS1 knockout mice exhibit a significant increase in serum proinflammatory cytokines, even in unchallenged conditions (6) , and adenovirus gene transfer of PIAS1 was able to ameliorate severe acute pancreatitis (SAP)-associated acute lung injury (ALI) in rats, linking PIAS1 with pneumonia and lung inflammation (7) . Overall, PIAS1 down-regulates inflammatory pathways at a variety of levels.
Ubiquitination of proteins is a posttranslational modification that influences a variety of housekeeping functions within the cell, the most common of which is the branding of proteins for proteasomal or lysosomal degradation (8) . The mechanism of protein ubiquitination is dependent on 1 of more than 1000 E3 ligases divided into three domain subfamilies: RING finger, U-box, and HECT (9, 10) . The existing~30 HECT domain E3 ligases remain poorly characterized (11) , and functional data are only available for a select few including E6AP, Smurf, and NEDD4 (11) . Among these HECT E3 ligases, HECTD2 has been linked to prion disease, Alzheimer's disease, and prostate cancer (12) (13) (14) .
However, substrates of HECTD2 have not yet been identified. Here, we discovered a new pathway of innate immunity that presents HECTD2 as a crucial regulator of cytokine secretion by controlling the stability of anti-inflammatory PIAS1.
RESULTS
HECTD2 targets PIAS1 for ubiquitination, thereby increasing NF-kB signaling PIAS1 degradation occurs in a ubiquitin-dependent manner and through the proteasome (fig. S1, A and B, and Fig. 1A ). Through screening, we further determined that HECT domain E3 ligase HECTD2 expression decreased PIAS1 ( fig. S1C ). HECTD2 expression specifically decreased PIAS1 but not other isoforms (Fig. 1B) ; two randomly selected HECT E3 ligases, KIAA0317 and HACE1, were also tested as negative controls ( fig. S1D ). Further, HECTD2 expression markedly decreased PIAS1's t 1/2 , whereas HECTD2 knockdown using short hairpin RNA (shRNA) stabilized PIAS1 protein (Fig. 1C ). The addition of purified HECTD2 with the full complement of E1 and E2 enzymes plus ubiquitin was sufficient to generate polyubiquitinated PIAS1 in vitro (Fig. 1D) . Because the Cys residue within the HECT domain active site is required for transferring ubiquitin to the substrate (15, 16) , we showed that HECTD2 C744S expression failed to decrease PIAS1 protein level ( fig. S1E ). Compared to wild-type (WT) and C749S mutant, HECTD2 C744S expression also did not decrease PIAS1's t 1/2 ( fig. S1F ). These studies suggest that C744S is a loss-of-function mutant, and C744 is a potential active site within HECTD2.
HECTD2 was detected in association with PIAS1 by coimmunoprecipitation (fig. S1G). Because PIAS1 is an important anti-inflammatory protein, we next investigated whether HECTD2 promotes inflammation. Indeed, HECTD2 overexpression drastically increased NF-kB promoter activity upon vehicle, lipopolysaccharide (LPS), tumor necrosis factor (TNF), or interferon-g (IFN-g) stimulation (Fig. 1E) , whereas HECTD2 knockdown drastically reduced NF-kB promoter activity (Fig. 1F) . Further, we transfected cells with PIAS1 shRNA 24 hours before HECTD2 overexpression. As shown in Fig. 1G , PIAS1 knockdown increased NF-kB promoter activity upon vehicle, LPS, TNF, or IFN-g stimulation but completely abrogated any additional effects induced by HECTD2 overexpression. LPS treatment increased HECTD2 protein and decreased PIAS1 protein in murine lung epithelial (MLE) (Fig. 1H ) and U937 cells ( fig. S1H ). LPS treatment also increased PIAS1's association to HECTD2 (Fig. 1H) . Last, LPS treatment drastically increased HECTD2 mRNA levels without changing the level of PIAS1 mRNA ( fig. S1I ). LPS treatment also drastically decreased PIAS1 protein t 1/2 (fig. S1J). We further identified K30 as the ubiquitin acceptor site within PIAS1 ( fig.   S2A ), because PIAS1 K30R exhibited resistance to ubiquitin and HECTD2 overexpression and an extended t 1/2 ( fig. S2 , B to D). PIAS1 K30R offered drastic resistance to HECTD2 and was able to suppress LPS-, TNF-, and IFN-induced NF-kB activation even upon coexpression with HECTD2 ( fig. S2E) .
We determined the PIAS1 binding site within the N terminus of HECTD2 (amino acids 393 to 397) ( fig. S3, A to E ). An alanine scan study within this region suggested that R397 is the preferred binding site for PIAS1, because HECTD2
R397A drastically lost binding with PIAS1 ( fig. S4A ). Compared to HECTD2 WT , HECTD2
R397A overexpression lost the ability to decrease PIAS1 protein levels ( fig. S4B ). HECTD2 R397A overexpression also failed to accelerate PIAS1's t 1/2 ( fig. S4C ). These studies suggested that HECTD2 is an authentic E3 ligase that ubiquitinates PIAS1 and functions as a proinflammatory protein in vitro. NF-kB promoter activity assays. 293T cells were cotransfected with Cignal NF-kB dual luciferase reporter plasmids along with empty or HECTD2 plasmid or control shRNA, HECTD2 shRNA, or PIAS1 shRNA 24 hours before HECTD2 plasmid expression. Twenty-four hours later, cells were treated with LPS (10 mg/ml), TNF (10 ng/ml), or IFN-g (10 ng/ml) for an additional 6 hours (F and G) or 18 hours. Cells were then collected and assayed for luciferase activity to evaluate NF-kB promoter activity. Means ± SEM (n = 3). (H) MLE cells were treated with LPS in a time-or dose-dependent manner; cells were then collected and assayed for HECTD2, PIAS, and actin immunoblotting. Endogenous HECTD2 was also immunoprecipitated (IP) and followed by PIAS1 and PIAS4 immunoblotting (n = 2). Source data in fig. S10 Fig. 2A) . PIAS1 is also phosphorylated at serine residue in cells ( Fig. 2A) . LPS drastically increased PIAS1 Fig. 2 . PIAS1 phosphorylation is required for HECTD2 targeting. (A) Endogenous PIAS1 was immunoprecipitated and followed by GSK3b and phosphoserine antibody immunoblotting (IB) (n = 2). IgG, immunoglobulin G. (B and C) MLE cells were treated with LPS in a time-or dose-dependent manner; cells were then collected and assayed for HECTD2, PIAS, and actin immunoblotting. Endogenous PIAS1 was also immunoprecipitated and followed by GSK3b, phosphoserine, and phosphothreonine immunoblotting (n = 2). (D) Endogenous PIAS1 protein half-life determination with control shRNA or GSK3b shRNA overexpression (n = 3). (E) MLE cells were transfected with increasing amounts of WT or constitutively activated GSK3b hypermutant plasmids for 18 hours before PIAS1 immunoblotting. The arrow indicates the overexpressed GSK3b (n = 2). (F) Endogenous PIAS1 protein half-life determination with WT GSK3b or hyperactive GSK3b plasmid overexpression. Arrow indicates the overexpressed GSK3b (n = 2). (G) Immunoblotting showing levels of endogenous GSK3b and PIAS1 protein in MLE cells transfected with either control shRNA or GSK3b shRNA followed by LPS treatment. Endogenous PIAS1 was also immunoprecipitated and followed by phosphoserine and phosphothreonine immunoblotting. (H) In vitro GSK3b kinase assay using PIAS1 as a substrate. GSK3b*, heatinactivated GSK3b (n = 2). (I) Protein half-life of WT, S13A, and S17A PIAS1 (n = 3). (J) MLE cells were transfected with WT, S13A, or S17A PIAS1 before being treated with LPS for up to 6 hours. Cells were then collected and assayed for V5-PIAS1. Overexpressed V5-PIAS1 was also immunoprecipitated using V5 antibody and followed by phosphoserine immunoblotting (n = 2). (K) Four biotin-labeled peptides were prebound to streptavidin and served as the bait for HECTD2 or GSK3b binding. After washing, proteins were eluted and processed for V5-HECTD2 or GSK3b immunoblotting (n = 2). Source data in fig. S11 . phosphorylation and GSK3b binding (Fig. 2, B and C). GSK3b knockdown using shRNA drastically stabilized PIAS1 protein in a cycloheximide t 1/2 study (Fig. 2D) . WT GSK3b overexpression decreased PIAS1 protein levels in a dose-dependent manner; however, PIAS1 protein levels decreased more markedly when we transfected cells with a constitutively activated GSK3b hypermutant plasmid (Fig. 2E) . Moreover, a cycloheximide t 1/2 study suggested that WT GSK3b ectopic expression decreased PIAS1's t 1/2 to~2.5 hours, whereas the more potent GSK3b hypermutant further decreased PIAS1's t 1/2 to~1 hour (Fig. 2F) . Further, GSK3b knockdown protected PIAS1 from phosphorylation and degradation in LPS treatment (Fig. 2G) . These studies suggested that GSK3b is an authentic regulator of PIAS1 protein stability. We further observed that GSK3b directly phosphorylated WT PIAS1, but not S13A, S17A, or S13/S17A mutant PIAS1, in an in vitro kinase assay (Fig. 2H ). Compared to WT PIAS1, S13A and S17A mutants drastically decreased binding to HECTD2 ( fig. S5F ). These PIAS1 mutants also exhibited much longer half-lives (Fig. 2I ), resisted degradation with HECTD2 coexpression ( fig. S5G ), and exhibited a marked decrease in phosphorylation and offered substantial protection against phosphorylation with LPS treatment (Fig. 2J and fig. S5H ). Last, we performed a peptide binding experiment (Fig. 2K) . Peptide with no phosphorylation (P1) and peptide with S13/S17A mutation (P4) were unable to bind to HECTD2; peptide with S17 phosphorylation (P3) offered drastically more HECTD2 binding compared to the peptide with S13 phosphorylation (P2). However, peptide with S13 phosphorylation (P2) offered drastically more GSK3b binding compared to the peptide with S17 phosphorylation (P3). Thus, PIAS1 phosphorylated S17 is the preferred binding site for HECTD2, whereas phosphorylated S13 is the preferred binding site for GSK3b.
HECTD2 contains a naturally occurring polymorphism at A19, which mislocalizes to the cytosol The single-nucleotide polymorphism (SNP) database analysis indicated a naturally occurring nonsynonymous G/C polymorphism (rs7081569) within HECTD2 (A19P) with an allele frequency of 8.5% throughout the population ( A19P displayed a similar ability to polyubiquitinate PIAS1 (Fig. 3A) . Also, both HECTD2
WT and HECTD2
A19P
bind to PIAS1 in vitro (Fig. 3B) . However, compared to HECTD2 WT , HECTD2
A19P overexpression lost the ability to decrease PIAS1 protein level (Fig. 3C ). Conditional expression of HECTD2
WT in MLE cells using a doxycycline-inducible plasmid resulted in PIAS1 protein degradation upon doxycycline treatment. However, HECTD2
A19P completely failed to decrease PIAS1 protein levels (Fig. 3, D WT exhibited comparable nuclear/cytosol signal, whereas YFP-HECTD2 A19P almost completely localized in the cytosol (Fig. 3H, upper panel) . By isolating nuclear and cytosol fractions, we observed that HECTD2
WT distribution was comparable in both nuclear and cytosol fractions, whereas HECTD2 A19P distribution was exclusively in the cytosol fraction ( fig. S6A ).
We further tested the HECTD2/PIAS1 interaction in the nucleus by fluorescence resonance energy transfer (FRET) analysis using a photobleaching method (18) . The results indicated that upon bleaching, there was decreased acceptor fluorescence (YPF) coupled with increased donor emission fluorescence [cyan fluorescent protein (CFP)], which suggest a HECTD2
WT interaction with PIAS1 within the nucleus in cells (Fig. 3H , lower panel). Because YFP-HECTD2 A19P almost completely resides in the cytosol, we did not observe any increased donor emission upon photobleaching in the nucleus. This suggested that nuclear entry of HECTD2 is required for PIAS1 targeting. Further deletional analysis indicated that the N terminus of HECTD2 is required for its nuclear entry, suggesting a potential nuclear localization signal ). Thus, nuclear entry of HECTD2 is both required and sufficient for PIAS1 targeting. This study also suggested that HECTD2
A19P is a loss-of-function polymorphism resulting from failed nuclear localization.
HECTD2
A19P is a loss-of-function E3 ligase polymorphism in vivo So far, our in vitro studies suggest that HECTD2 A19P is a loss-offunction polymorphism. To extend the above observations in vivo, mice were infected with an empty lentivirus or lentivirus encoding either HECTD2 or HECTD2
A19P
. Mice were then challenged with Pseudomonas aeruginosa (PA103). P. aeruginosa, a gram-negative bacterium, is a significant contributor to nosocomial pneumonia (20) , sepsisassociated ALI, and acute respiratory distress syndrome (ARDS) (21) . Consequently, clinically isolated PA103 has been widely used in the animal model of ARDS (22) (23) (24) (25) . Mice were euthanized before analysis of parameters of inflammatory injury. HECTD2
WT expression, but not HECTD2
, significantly augmented PA103-induced lung injury. Specifically, HECTD2
WT gene transfer significantly increased lavage protein concentrations and cell counts, and produced histologic evidence of severe lung inflammation (Fig. 4, A , B, and G). In addition, HECTD2
WT gene transfer significantly increased lavage cytokine levels compared to mice receiving an empty vector or HECTD2 A19P with PA103 infection (Fig. 4, D to F) . Also, lentiviral gene transfer of empty, HECTD2 WT , or HECTD2 A19P did not significantly alter bacterial load (Fig. 4C) . Last, HECTD2
WT drastically reduced PIAS1 protein expression in the lung, whereas HECTD2 A19P did not significantly alter PIAS1 levels compared to the empty control (Fig. 4H) . All of the biologic effects, except bacterial loads, were less pronounced after gene transfer of HECTD2
. These in vivo studies further support HECTD2 A19P as a loss-of-function polymorphism.
HECTD2
A19P polymorphism is characterized in ARDS patient cohorts Because the HECTD2 A19P polymorphism offers blunted cytokine response in our animal model (Fig. 4) , it is reasonable to hypothesize that HECTD2 A19P is a protective protein variant in patients who harbor the polymorphism. Strikingly, we sequenced the genomic DNA from 63 patients (47% male and 95% Caucasian) with or at-risk for ARDS and found 0 carriers for the rs7081569 polymorphism (0 of 63). Examination of the HECTD2 genotype in the 1000 Genomes Project cohort (REF) demonstrated an 8.5% prevalence of the rs7081569 polymorphism distributed evenly by gender (P = 0.267) but differentially by race (P = 0.012, Table 2 ). We performed the c 2 test to examine the association between the rs7081569 polymorphism in our ARDS cohort WT and HECTD2 A19P as the E3 ligase (n = 3). (B) Endogenous PIAS1 protein was immunoprecipitated from cell lysate using PIAS1 antibody and coupled to protein A/G beads. PIAS1 beads were then incubated with in vitro synthesized products expressing his-V5-HECTD2 mutants (top). After washing, proteins were eluted and processed for V5-HECTD2 immunoblotting (bottom) (n = 2). (C) MLE cells were transfected with increasing amounts of WT or A19P HECTD2 plasmids for 18 hours before being assayed for PIAS1 protein immunoblotting (n = 3). (D and E) MLE cells were transfected with an inducible HECTD2 WT or HECTD2 A19P plasmid under control of exogenous doxycycline. Cells were treated with doxycycline for various times and dose. Cells were then collected, and cell lysates were analyzed for HECTD2 and PIAS1 by immunoblotting (n = 2). (F) Half-life study of endogenous PIAS1 upon HECTD2
WT or HECTD2 A19P overexpression (n = 2). (G) 293T cells were cotransfected with Cignal NF-kB reporter plasmids and empty, HECTD2 WT , or HECTD2 A19P plasmid for 18 hours. Cells were then exposed to LPS or TNF for additional 18 hours before being assayed for NF-kB promoter activity. Means ± SEM (n = 3). (H) MLE cells were cotransfected with CFP-PIAS1 and YFP-HECTD2 WT or YFP-HECTD2
A19P
.
YFP-HECTD2
WT and YFP-HECTD2 A19P nuclear/cytosol fluorescent signals were measured and quantified (n > 20, right graph, *P < 0.0001 compared to WT). Cells were also subjected to irreversible photobleaching of YFP acceptor signal using a 514-nm laser. The emission fluorescence levels of both the donor CFP-PIAS1 and acceptor YFP-HECTD2
WT or YFP-HECTD2 A19P before and after acceptor photobleaching are shown in the lower panel; the region of interest across the nucleus is marked with a red arrow. The green arrow on the graph indicates donor CFP-PIAS1 signal before and after the photobleaching. Scale bar, 10 mm (n > 10). Source data in fig. S12 and table S3.
and control European descendants (Table 3 and table S1 ). The percentage of the genotypes CG or CC were significantly higher in the healthy controls (1000 Genomes Projects) compared to that in the ARDS cohort (13% versus 0%, P = 0.003), suggesting a potentially protective effect of the C allele in the HECTD2 gene against the development of lung injury.
PIAS1 knockdown induces lung injury in vivo
To further confirm whether HECTD2 induces an inflammatory response through PIAS1 in vivo, mice were first infected with lentivirus encoding control shRNA or PIAS1 shRNA and then challenged with LPS (intratracheally, 3 mg/kg). Both LPS and PIAS1 knockdown significantly increased lavage protein concentrations, lavage cell counts, lavage cytokines, and cell infiltrates (Fig. 5, A, B , and D to G). Further, PIAS1 knockdown significantly exacerbated lavage cell counts, TNF levels, and cell infiltrates induced by LPS (Fig. 5, B , D, and G) without affecting lavage protein, IL-1, or IL-6 levels compared to the control shRNA (Fig. 5 , A, E, and F). We also showed that innate murine lungs have very low levels of HECTD2, which increase significantly upon LPS stimulation (Fig. 5C ). Both LPS and lentivirus encoding PIAS1 shRNA effectively reduce PIAS1 protein levels (Fig. 5C ). Collectively, this experiment suggested that PIAS1 is an important suppressor of inflammation in the lung, and HECTD2 induces an inflammatory response in the lung partially through PIAS1.
HECTD2 knockdown ameliorates Pseudomonas-induced lung injury in vivo
To further confirm the role of HECTD2 in pneumonia and evaluate whether HECTD2 is required in lung inflammation, we pursued in vivo knockdown studies. Mice were first infected with lentivirus encoding control shRNA or HECTD2 shRNA and then challenged with PA103. HECTD2 knockdown significantly decreased lavage protein concentrations, lavage cell counts, and cell infiltrates without affecting bacterial load (Fig. 6, A to C and H) . Further, HECTD2 knockdown significantly decreased lavage cytokine levels in PA103-infected mice (Fig. 6 , D to F), and these mice had improved survival (Fig. 6G) . Last, lentivirus encoding HECTD2 shRNA effectively reduced HECTD2 protein level against PA103 infection, leading to an increase in PIAS1 protein level in the lung (Fig. 6I) . Collectively, the above studies suggest for the first time that HECTD2 plays an integral role in mediating cytokine-driven inflammation via the PIAS1-cytokine axis and may serve as a potential pharmaceutical target. A small-molecule inhibitor of HECTD2 exhibits anti-inflammatory activity HECTD2 harbors a conserved HECT domain within its C terminus (11, 26) . Because the HECT domain carries out the E3 ligase activity of transferring ubiquitin to the substrate (11, 26), we hypothesized that small-molecule inhibition of the HECT domain would disrupt HECTD2 targeting its substrate, PIAS1. We first constructed a homology model using the NEDD4 HECT domain (27, 28) (2XBF.pdb) (Fig. 7A) . Using molecular docking analysis and score-ranking operations on the predicted HECTD2-HECT domain three-dimensional structure model, we assessed potential ligands that might fit the HECT domain cavities (Fig. 7B) . Through the LibDock program from Discovery Studio 3.5, we were able to screen the potential ligands for the HECTD2-HECT domain. G723, K470, and T526 residues within the HECT domain are important for interacting with inhibitors ( fig. S8A ). We were able to test one of the selected compounds, termed BC-1382, in an in vitro binding assay (Fig. 7C) . The result suggested that BC-1382 is a potent inhibitor of HECTD2 with IC 50 (median inhibitory concentration) ≈ 5 nM toward disrupting the HECTD2/PIAS1 interaction. BC-1382 drastically increased PIAS1 protein level in a nonstimulus condition with IC 50 ≈100 nM ( fig. S8B) . PIAS3, PIAS4, and HECTD2 protein levels appeared to be unchanged. BC-1382 did not alter mRNA levels of PIAS1, PIAS4, or HECTD2 ( fig. S8C ). BC-1382 also improved PIAS1 protein stability by increasing its t 1/2 ( fig. S8D ). BC-1382 suppressed LPS-induced PIAS1 degradation and restored PIAS1 protein levels at 800 nM ( fig. S8E) . Last, BC-1382 was able to suppress LPSinduced proinflammatory cytokines released by human peripheral blood mononuclear cells (PBMCs) (fig. S8F ). To assess the in vivo antiinflammatory activity of BC-1382, we tested it using P. aeruginosa-and LPS-induced pneumonia models. Briefly, C57BL/6J mice were challenged per mouse, n = 8 mice per group) were determined (time, hours). Mice were carefully monitored over time; moribund, preterminal animals were immediately euthanized and recorded as deceased. Kaplan-Meier survival curves were generated using SPSS software (P = 0.001). (H) H&E staining was performed on lung samples from (A). (I) PIAS1, HECTD2, and actin immunoblots from homogenized lung samples. Scale bar, 100 mm; original magnification, ×10. Data are average of two experiments (Student's t test on means ± SEM). (A to G) n = 6 to 9 mice per group. NS, not significant. Source data in fig. S13 and table S6.
intratracheally with PA103 (10 4 CFU per mouse) or LPS (3 mg/kg). BC-1382 was given through intraperitoneal injection (10 mg/kg) at the same time. Eighteen hours later, mice were euthanized, and lungs were lavaged with saline. BC-1382 did not appear to affect BAL bacteria (Fig. 7D) . However, it significantly decreased lavage protein concentrations, lavage cell counts, and cell infiltrates in both PA103-stimulated (Fig. 7 , E, F, and H) and LPS-stimulated ( fig. S9, A, B, and D) mice. Further, BC-1382 significantly decreased lavage cytokine levels in both models (Fig. 7G and fig. S9C ). Last, PA103 very effectively increased HECTD2 protein level and decreased PIAS1 in the lung. However, PIAS1 protein level is preserved by BC-1382 (Fig. 7I) . Hence, smallmolecule targeting of the HECTD2-PIAS1 pathway reduces the severity of cytokine-driven lung inflammation (Fig. 8) .
DISCUSSION
An overactivated innate immune system triggered by invading pathogens will release large amounts of proinflammatory cytokines (that is, cytokine storm), leading to the devastating effects of pulmonary edema, multiorgan failure, and shock (29, 30) . Current efforts using systemic corticosteroids to block cytokine storm have shown many side effects in clinical trials (31) . Other biological approaches (for example, TNF-a and TNF receptor antibodies) are greatly limited because only one target (a receptor or cytokine) is selected for inhibition (32) . However, many inflammatory diseases are intricate disorders, whereby a combination of inflammatory mediators is released from the activation of multiple receptors. Hence, there is an unmet scientific need to discover a molecular target that could lead to a new generation of agents that can potently modulate innate immunity and the host inflammatory response. This study provides a link between HECTD2 and PIAS1 in innate immunity and sets the stage for future analysis of HECTD2 polymorphisms in a much bigger cohort of patients with many other inflammatory diseases.
We showed that HECTD2 is a bona fide E3 ligase that triggers the ubiquitination and degradation of PIAS1 for exacerbated inflammation in vivo and in vitro. In essence, HECTD2 appeared to promote inflammation in part by destabilizing PIAS1, thus preventing it from controlling transcriptional regulatory pathways like NF-kB. PIAS1 knockdown itself is sufficient to increase NF-kB promoter activity upon vehicle, LPS, TNF, or IFN-g stimulation, but it totally abrogated any additional effects induced by HECTD2 overexpression (Fig. 1G ). An in vivo study also suggested that PIAS1 is an important suppressor of inflammation in the lung, and HECTD2 induces an inflammatory response in the lung partially through PIAS1. Moreover, GSK3b was found as a regulator that phosphorylates PIAS1, thereby serving as a molecular signal for HECTD2 targeting. Specifically, phosphorylated S13 is the preferred binding site for GSK3b, whereas phosphorylated S17 is the preferred binding site for HECTD2 (Fig. 2K) . It is highly likely that PIAS1 S13 is a priming phosphorylation site by another kinase(s) for GSK3b binding, which leads to the phosphorylation of S17. The latter motif served as the phosphodegron for HECTD2 targeting. Similar mechanisms of substrate targeting by GSK3b phosphodegron motifs have been described (33, 34) . Previous studies of PIAS1 activity upon proinflammatory stimuli identified the IkB kinase a (IKKa)-mediated phosphorylation of PIAS1 at S90 to swiftly repress inflammatory gene transcription (3). However, this phosphorylation occurred very rapidly (within 10 to 30 min) (3). Our study, however, found that GSK3b regulates PIAS1 protein stability and describes a mechanism of PIAS1 basal protein turnover controlled constitutively by HECTD2, providing an internal checkpoint for the cell to shut off the antiinflammatory pathway, a mechanism hijacked by endotoxins to shut down PIAS1 and propel cytokine storm.
We revealed a naturally occurring amino acid variant in HECTD2 that is present at a frequency of~8.5% of the population (HECTD2   A19P ). This loss-of-function polymorphism causes the mislocalization of itself in the cytosol, leaving it unable to enter the nucleus where PIAS1 continues its anti-inflammatory activity. So far, many genetic diseases have been linked to the mislocalization of nuclear proteins because of SNPs within the NLS region (35) . For example, missense mutations within the NLS of sex-determining region Y protein (SRY) that reduce the nuclear localization of SRY have been characterized in patients with Swyer syndrome (36) . However, our preliminary results based on our ARDS cohorts (63 patients) showed that the HECTD2 A19P polymorphism is a protected mutant, at least in the disease of ARDS. One of the clinical hallmarks of patients with pneumonia-or sepsis-induced ARDS is a robust acute host inflammatory response triggered by invading pathogens (37) . Specifically, the innate immune system is triggered to secrete large amounts of proinflammatory cytokines (that is, cytokine storm), which further causes tissue injury and organ failure (38) . The HECTD2 A19P polymorphism offers blunted cytokine response in our animal model (Fig. 4) , which is consistent with the fact that HECTD2
A19P is a protective protein variant in ARDS patients who harbor the polymorphism. Further prospective study in disease cohorts is required to validate this observation. HECTD2 A19P may also be an important and protective polymorphism in many other inflammatory diseases.
The discovery of HECTD2 as a stimulator of proinflammatory signaling provided the mechanistic platform that led to the design, synthesis, and biological evaluation of a first-in-class small-molecule inhibitor that exerted robust anti-inflammatory activity by impairing cytokine release. We developed a small-molecule inhibitor of HECTD2, BC-1382, by using the readily available NEDD4 HECT crystal structure to generate a homology model of HECTD2 C-terminal structure. We had previously used a similar approach to design inhibitors for the proinflammatory protein FBXO3 (29, 30) . BC-1382 was able to drastically attenuate LPS-and P. aeruginosa-induced lung injury (Fig. 7  and fig. S9 ). Future studies will focus on evaluating the safety profile, distribution, elimination, and metabolism of this chemical entity in other inflammatory models beyond pneumonia and sepsis. Successful results from these studies will provide the basis for translating to clinical application in acute and chronic inflammatory illness.
MATERIALS AND METHODS

Study design
Our goal in this study was to investigate the role of HECTD2 in innate immunity and models of experimental lung injury. Several in vitro approaches were used to determine the proinflammatory function Fig. 8 . One mechanism by which microbial infection or stimuli can robustly trigger inflammation is to decrease anti-inflammatory proteins such as PIAS1 in cells. Specifically, during microbial infection, HECTD2 (R397) targets PIAS1 for its ubiquitination at K30; this process is facilitated by GSK3b phosphorylation of PIAS1 at S17. In this pathway, WT HECTD2 potently activates cytokine-driven inflammation, whereas we identified a naturally occurring, mislocalized, hypofunctional variant of HECTD2 (A19P) that lowers the amount of cytokine secretion. A smallmolecule HECTD2 inhibitor, BC-1382, decreased inflammation in an animal model of ARDS by antagonizing the actions of HECTD2 on PIAS1, allowing PIAS1 to continue to suppress cytokine signaling.
of HECTD2. We also determined the molecular interplay between HECTD2 and its substrate, PIAS1. To further test HECTD2 in vivo, C57BL6 mice were given lentivirus encoding HECTD2, A19P variant, or HECTD2 shRNA. Seven days later, mice were infected with P. aeruginosa to mimic the lung injury. Mice were randomized in different groups, but the experimenter was not blinded to the group identities. Human genomic DNA was also collected and isolated from subjects diagnosed with ARDS after obtaining informed consent. We tried to differentiate the HECTD2 A19P polymorphism in healthy and ARDS patient cohorts.
Materials
Sources of the MLE, A549, and 293T cell lines were described previously (39, 40) . Purified ubiquitin, E1, E2, MG132, leupeptin, and cycloheximide were purchased from Calbiochem. Mouse monoclonal V5 antibody, the pcDNA3.1D cloning kit, E. coli One Shot competent cells, the pENTR Directional TOPO cloning kits, Gateway mammalian expression system, and genomic extraction kit were from Invitrogen. Fluorescent vector pAmCyan1-C1 and pZsYellow1-N1 and Lentivirus kit were from Clontech. PBMCs were from Sanguine Life Sciences. The HECT domain E3 ligase complementary DNA, scramble shRNA, HECTD2, PIAS1, and GSK3b shRNA sets were purchased from Open Biosystems. Nucleofector transfection kits were from Amaxa. Immobilized protein A/G beads were from Pierce. In vitro transcription and translation (TnT) kits were from Promega. The Cignal NF-kB Reporter Luciferase Kit (CCS-013L) was from Qiagen. Complete proteasome inhibitors were from Roche. HECTD2 antibodies were from Abcam and Santa Cruz Biotechnology. PIAS and GSK3b antibodies were from Cell Signaling and Santa Cruz Biotechnology. IL-1b, TNF-a, and IL-6 mouse ELISA kit, human cytokine array, and TNF-a and IFN-g proteins were from R&D Systems. LPS (E. coli) was from Sigma. Peptides were custom-synthesized from CHI Scientific. DNA sequencing was performed at Genewiz. All small-molecule compound analysis was performed by the University of Pittsburgh Mass Spectrometry and Nuclear Magnetic Resonance facility.
Human samples
This study was approved by the University of Pittsburgh Institutional Review Board. After obtaining informed consent, we collected blood from subjects diagnosed with ARDS (clinical diagnosis). Genomic DNA was isolated from whole blood (Puregene DNA Isolation Kit, Qiagen).
Cell culture MLE cells were cultured in Dulbecco's modified Eagle's medium-F12 (Gibco) supplemented with 10% fetal bovine serum (DMEM-10). PBMCs were thawed and cultured in RPMI medium supplemented with 10% fetal bovine serum following the manufacturer's protocol (Sanguine Life Sciences). For HECTD2 overexpression in 293T cells, Fugene6HD transfection reagent was used following the manufacturer's protocol. Twenty-four hours later, cells were treated with LPS at 0 to10 mg/ml, TNF at 10 ng/ml, or IFN-g at 10 ng/ml for an additional 18 hours. For HECTD2 or GSK3b knockdown studies in MLE cells, scramble, HECTD2, or GSK3b shRNA was used to transfect cells for 48 hours using electroporation. For drug treatment, compounds were solubilized in dimethyl sulfoxide before being added to the cells for up to 18 hours. Cell-free medium was collected and analyzed for cytokine release. Cell lysates were prepared by brief sonication in 150 mM NaCl, 50 mM tris, 1.0 mM EDTA, 2 mM dithiothreitol (DTT), 0.025% sodium azide, and 1 mM phenylmethylsulfonyl fluoride (buffer A) at 4°C. For half-life study, MLE cells were exposed to cycloheximide (40 mg/ml) in a time-dependent manner for up to 6 hours. Cells were then collected and assayed for HECTD2 or PIAS1 immunoblotting.
In vitro protein binding assays PIAS1 protein was immunoprecipitated from 1 mg of cell lysate using PIAS1 antibody (rabbit) and coupled to protein A/G beads. PIAS1 beads were then incubated with in vitro synthesized products (50 ml) expressing HIS-V5-HECTD2 mutants. After washing, proteins were eluted and processed for V5-HECTD2 immunoblotting. Similarly, HECTD2 was immunoprecipitated from 1 mg of cell lysate using HECTD2 antibody (goat) and coupled to protein A/G beads. HECTD2 beads were then incubated with in vitro synthesized products (50 ml) expressing HIS-V5-PIAS1 mutants. After washing, proteins were eluted and processed for V5-PIAS1 immunoblotting.
In vitro peptide binding assays Biotin-labeled peptides were first coupled to streptavidin-agarose beads for 1 hour. Beads were then incubated with purified HECTD2 or GSK3b for 18 hours. After washing, proteins were eluted and processed for V5-HECTD2 or GSK3b immunoblotting.
In vitro ubiquitin conjugation assays
The assay was performed in a volume of 25 ml containing 50 mM tris (pH 7.6), 5 mM MgCl 2 , 0.6 mM DTT, 2 mM adenosine triphosphate, E1 (1.5 ng/ml), Ubc5 (10 ng/ml), Ubc7 (10 ng/ml), ubiquitin (1 mg/ml) (Calbiochem), 1 mM ubiquitin aldehyde, and in vitro synthesized V5-PIAS1 and HECTD2. Reaction products were processed for V5 immunoblotting.
NF-kB promoter assay
Cignal NF-kB Reporter luciferase plasmids were cotransfected with empty, HECTD2, control shRNA, PIAS1 shRNA, or HECTD2 shRNA for 24 to 48 hours before vehicle, LPS, TNF, or IFN-g treatment for an additional 6 to 18 hours. Cells were then collected and assayed for firefly and Renilla luciferase activity. NF-kB promoter activity was normalized by firefly and Renilla luciferase activity ratio.
Molecular docking studies and compound design
The docking experiments were carried out by using software from Discovery Studio 3.5. A library containing 500,000 approved or experimental drugs was first used to screen potential ligands for HECTD2. HECTD2-HECT domain structural analysis revealed several potential binding cavities for inhibitor targeting. These binding cavities were adopted into the LibDock algorithm to screen for the optimum inhibitor. On the basis of the docking and best-fit analysis of suitable ligands, BC-1382 and other high-scoring molecules were selected and further tested in vitro.
Real-time quantitative polymerase chain reaction, cloning, and mutagenesis Total RNA was isolated and reverse transcription was performed followed by real-time quantitative polymerase chain reaction (qPCR) with SYBR Green qPCR mixture as described (41) . All mutant PIAS1 and HECTD2 plasmid constructs were generated using PCR-based approaches using appropriate primers and subcloned into a pcDNA3.1D/V5-His vector.
Lentivirus construction
To generate lentivirus encoding HECTD2, Plvx-HECTD2 plasmid was cotransfected with Lenti-X HTX packaging plasmids (Clontech) into 293FT cells following the manufacturer's instructions. Seventy-two hours later, virus was collected and concentrated using Lenti-X concentrator.
Cytokine arrays
Cytokine Array, Panel A (R&D Systems) was used to profile 36 cytokines in cell-free medium or murine lavage. Each cytokine signal value was quantified using ImageJ software on the basis of the relative signal intensities and graphed.
SNP genotyping
To elucidate the genotype of acute lung injury patients, we amplified a 700-base pair DNA fragment flanking the rs7081569 polymorphism in the HECTD2 gene using genomic DNA (n = 63), and the forward primer ATGAGTGAGGCGGTTCGGGT and reverse primer TGTAC-CATATGAAAAATAAAACCATCACTGATG. These PCR products were analyzed using agarose gel electrophoresis, and the correct DNA fragment was collected and purified using the Qiagen Gene Clean Kit. The purified PCR product was sequenced with an internal primer TCCCAACTCCCGCCGT through the company Genewiz.
FRET analysis
Cells were plated and cotransfected with CFP-PIAS1 and YFP-HECTD2 Wt or YFP-HECTD2 A19P plasmids as described (18, 40) . Interactions were detected at the single-cell level by using a combination laserscanning microscope system (Nikon A1). Briefly, MLE cells were transfected with CFP and YFP plasmid for 24 hours. Cells were fixed with 4% paraformaldehyde for 10 min. To achieve excitation, the 458-or 514-nm line of an argon ion laser was focused through the ×60 oil differential interference contrast objective lens onto the cell. Emissions of CFP (the FRET donor) and YFP (the FRET acceptor) were collected, respectively. Photobleaching was performed with 100% intensity of a 514-nm laser for 2 s. FRET quantitation of fluorescence images was generated using Nikon NIS-Elements software. Here, the emission fluorescence of both the donor CFP-PIAS1 and acceptor YFP-HECTD2 (Fig. 3H ) before and after acceptor photobleaching was measured around the region of interest (nucleus, marked in red arrow). Positive FRET is indicated by the decreased acceptor fluorescence (YPF) coupled with increased donor emission fluorescence (CFP) upon photobleaching.
Animal studies All procedures were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. For pneumonia studies, C57BL6 mice were deeply anesthetized using a ketamine/xylazine mixture, and the larynx was well visualized under a fiber optic light source before endotracheal intubation with a 3/400 24-gauge plastic catheter. Lentivirus (10 7 CFU) encoding genes for HECTD2, HECTD2 A19P , or HECTD2 shRNA was instilled intratracheally for 144 hours before administration of P. aeruginosa (strain PA103, 10 4 CFU per mouse, intratracheally) for 18 hours, after which animals were euthanized and assayed for BAL protein, cell count, bacterial count, cytokines, and lung infiltrates (29, 30, 34) . Survival studies of mice were performed on mice that were given P. aeruginosa (strain PA103, 10 5 CFU per mouse, intratracheally, 8 mice per group). Mice were carefully monitored over time; moribund, preterminal animals were immediately euthanized and recorded as deceased. For drug studies, mice were deeply anesthetized as above. PA103 (10 4 CFU) or LPS (3 mg/kg) was instilled intratracheally before BC-1382 (10 mg/kg) was administered to the mice through an intraperitoneal injection. Eighteen hours later, animals were euthanized and analyzed as above.
Statistical analysis
Statistical comparisons were performed with mean ± SEM for continuous variables. All data were statistically analyzed by unpaired Student's t test. Kaplan-Meier survival curves were generated for animal studies. c
2 test was used to analyze human data. All analyses will be performed using SPSS (IBM) or Stata Statistical Software: Release 10.1 (StataCorp LP).
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